**7. Conclusion**

The drawbacks of global schistosomiasis monotherapy with **PZQ** have motivated considerable work to generate a pipeline of new drug leads for further development. In recent years, screening studies agnostic on candidates' modes of action have complemented more target-focused work. The limits of both approaches are evident, as hit compounds with excellent *in vitro* activity often fail to ameliorate a *Schistosoma* infection in *in vivo* models. This calls for better understanding of the pharmacokinetics required of effective schistosomicides, better screening techniques to approximate *in vivo* conditions, and more research into host-parasite interaction. The embrace of these challenges by the drug development community is encouraging.
